Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology–European Academy of Allergy and Clinical Immunology PRACTALL consensus report - 28/11/12
Doi : 10.1016/j.jaci.2012.10.017
Hugh A. Sampson, MD a, ⁎ 
, Roy Gerth van Wijk, MD b, Carsten Bindslev-Jensen, MD, PhD c, Scott Sicherer, MD a, Suzanne S. Teuber, MD d, A. Wesley Burks, MD e, Anthony E.J. Dubois, MD f, Kirsten Beyer, MD g, Philippe A. Eigenmann, MD h, Jonathan M. Spergel, MD, PhD i, Thomas Werfel, MD j, Vernon M. Chinchilli, PhD k
, Roy Gerth van Wijk, MD b, Carsten Bindslev-Jensen, MD, PhD c, Scott Sicherer, MD a, Suzanne S. Teuber, MD d, A. Wesley Burks, MD e, Anthony E.J. Dubois, MD f, Kirsten Beyer, MD g, Philippe A. Eigenmann, MD h, Jonathan M. Spergel, MD, PhD i, Thomas Werfel, MD j, Vernon M. Chinchilli, PhD k a Mount Sinai School of Medicine, New York, NY
b Erasmus Medical Center, Rotterdam, The Netherlands
c Odense University Hospital, Odense, Denmark
d University California-Davis School Medicine, Davis, Calif
e University North Carolina School of Medicine, Chapel Hill, NC
f University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergy, and the GRIAC Research Institute, Groningen, The Netherlands
g Charité University Hospital, Clinic for Pediatric Pneumology and Immunology, Berlin, Germany
h Children’s University Hospital of Geneva, Geneva, Switzerland
i Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
j Hannover Medical School, Hannover, Germany
k Pennsylvania State University College of Medicine, Hershey, Pa
Corresponding author: Hugh A. Sampson, MD, Department of Pediatrics, Box 1198, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574.Key words : Food allergy, oral food challenge, double-blind, placebo-controlled food challenge
Abbreviations used : AD, APT, DBPCFC, LOAEL, ML, NO, NOAEL, OFC, SPT
Plan
| Disclosure of potential conflict of interest: H. A. Sampson is on the Danone Scientific Advisory Board; has received consultancy fees from Allertein Therapeutics and the Food Allergy Initiative (FAI); is employed by Mount Sinai Medical School; has received research support from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH); has received royalties from Elsevier-Wiley and UpToDate; has received travel expenses from the NIAID; and is 42.5% shareholder of Herbs Springs, LLC. R. Gerth van Wijk has received travel support from the European Academy of Allergy and Clinical Immunology (EAACI); is on the board for the World Allergy Organization and EAACI; has received consultancy fees from MSD, Crucell, and Haarlems Allergenen Lab; is employed by Erasmus Medical Center; has received research support from Zon-MW, STW, and Biomay; has received lecture fees from Allergopharma; and receives royalties from Handboek Allergologie, Het Allergie Formulatius, and Het Allergie Boek. C. Bindslev-Jensen has received lecture fees from MSD and Thermo-Fisher. S. Sicherer has received consultancy fees from the FAI. S. S. Teuber has consulted for Sanofi-Aventis. A. W. Burks has received grants and support for travel from the NIH/NIAID; is on boards for the NIH HAI, US Food and Drug Administration (FDA), and American Academy of Allergy, Asthma & Immunology (AAAAI); has consulted for Dannon Company, Merck & Co, Exploramed Development Intelliject, McNeil Nutritionals, Novartis Pharma AG, and Schering-Plough; has received grants from the Food Allergy & Anaphylaxis Network, the FAI, the NIH, and Wallace Research Foundation; has received royalties from UptoDate; has received payment for educational presentations from Current Views; and owns stock or stock options in Allertein and MastCell Pharmaceuticals. A. Dubois has received travel and hotel costs from the EAACI, is on the ALK-Abelló Adrenaline Board, and has received research support from ALK-Abelló. K. Beyer has received consultancy fees from Danone, Novartis, and ALK-Abelló; has received research support from the German Research Foundation, European Union, Danone, and Foundation of the Treatment of Peanut Allergy; and has received lecture fees from Danone, Phadia, Infectopharm, CSL Behring, Novartis, UCB, Meda Pharma, and Med Update. P. A. Eigenmann has received travel support from the EACCI; has consulted for DBV Technologies, Danone, Nestlé, and ALK-Abelló; has received grants from LETI and Nestlé; has received payment for lectures from Stallergenes, Sodilac, and Phadia; has received royalties from UpToDate and Elsevier; and owns stock or stock options in DBV Technologies. J. M. Spergel is on the advisory board for and has stock/stock options in DBV; has received consultancy fees from Danone; has received research support from the Department of Defense, Ception, NIH, and Nutricia; has received lecture fees from Abbott and Nutricia; receives royalties from UpToDate; and has received payment for development of educational presentations from MEI. T. Werfel has received travel support from the EAACI. V. M. Chinchilli has received travel support from the AAAAI. |
© 2012
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 130 - N° 6
P. 1260-1274 - décembre 2012 Retour au numéro
Article précédent
- The long-acting β-adrenergic agonist controversy in asthma: Troublesome times!
- Stanley J. Szefler, William W. Busse
- Sleep and allergic disease: A summary of the literature and future directions for research
- Daphne Koinis-Mitchell, Timothy Craig, Cynthia A. Esteban, Robert B. Klein
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?